5-bromo-2-methylfuran-3-carboxylic acid | 850553-54-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: 5-bromo-2-methylfuran-3-carboxylic acid
• CAS: 850553-54-7
• 化学式: C₆H₅BrO₃
• 分子量: 205.008
• InChiKey: YQROOKGRFHAYEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-bromo-2-methylfuran-3-carboxylic acid 在 4-二甲氨基吡啶 、 四(三苯基膦)钯 、 palladium on activated charcoal 、 水 、 氢气 、 sodium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 甲醇 、 乙二醇二甲醚 、 二氯甲烷 、 水 、 乙腈 为溶剂， 20.0~85.0 ℃ 、100.0 kPa 条件下， 反应 16.0h， 生成 2-[4-(5,6-dihydro-4H-cyclopenta[d][1,3]thiazol-2-ylcarbamoyl)-5-methylfuran-2-yl]benzoic acid
  参考文献：
  名称：

  Discovery and hit-to-lead optimization of novel allosteric glucokinase activators

  摘要：

  We report on a hit generation and hit-to-lead program of a novel class of glucokinase activators (GKAs). Hit compounds, activators at low glucose concentration only were identified by vHTS. Scaffold modification reliably afforded activators also at high substrate level. Potency was increased by introduction of a hydrogen bond acceptor as proposed by molecular docking. Replacement of the initial alkylene linkers with a rigid 1,2-phenylene motif followed by further studies eventually furnished a series of potent lead compounds exhibiting steep SAR. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.128
• 作为产物：
  描述：

  2-甲基-3-糠酸 在 溴 作用下， 生成 5-bromo-2-methylfuran-3-carboxylic acid
  参考文献：
  名称：

  Gilman et al., Recueil des Travaux Chimiques des Pays-Bas, 1932, vol. 51, p. 407,409

  摘要：

  DOI：

文献信息

• Diacylglycerol acyltransferase inhibitors
  申请人：Bolin Robert David

  公开号：US20070123504A1

  公开（公告）日：2007-05-31

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了式(I)的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如肥胖、2型糖尿病和代谢综合征等疾病是有用的。
• [EN] FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE FURANE UTILISES COMME ANTAGONISTES DU RECEPTEUR EP4
  申请人：PHARMAGENE LAB LTD

  公开号：WO2005037812A1

  公开（公告）日：2005-04-28

  A compound of formula: (I); or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 alkyl group; or (ii)an optionally substituted C5-7 aryl; and the other of R2 and R5 is the other group; m and n can be 0 or 1, and m + n = 1 or 2 RN is H or optionally substituted C1-4 alkyl R3 is either: (i) carboxy; (ii) a group of formula: (II); (iii) a group of formula: (III); wherein R is optionally substituted C1-7 alkyl, C5-20 aryl, or NRN3RN4 , where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; or (iv) tetrazol-5-yl.

  一种化合物的化学式为：(I); 或其盐、溶剂合物和化学保护形式，其中R2和R5中的一个是：(i) H或可选择地取代的C1-4烷基；或(ii)可选择地取代的C5-7芳基；另一个是另一种基团；m和n可以为0或1，且m + n = 1或2；RN为H或可选择地取代的C1-4烷基；R3可以是：(i)羧基；(ii)化学式为(II)的基团；(iii)化学式为(III)的基团；其中R可选择地取代的C1-7烷基、C5-20芳基或NRN3RN4，其中RN3和RN4分别选择自可选择地取代的C1-4烷基；或(iv)噻唑-5-基。
• 複素環化合物
  申请人：武田薬品工業株式会社

  公开号：JP2016065023A

  公开（公告）日：2016-04-28

  【課題】本発明は、優れたＴｙｋ２阻害作用を有し、自己免疫疾患または炎症性疾患（特に、炎症性皮膚疾患）（例えば、全身性エリテマトーデス、炎症性腸疾患、乾癬、関節リウマチ、シェーグレン症候群、ベーチェット病、多発性硬化症、アトピー性皮膚炎等）等の予防または治療剤を提供する。【解決手段】本発明は3-アミノ-5-(ジシクロプロピルメチル)-7-(4-フルオロ-1-メチル-5-(モルホリン-4-イル)-1H-ピラゾール-3-イル)-1,5-ジヒドロ-4H-ピラゾロ[4,3-c]ピリジン-4-オン等に関する。【選択図】なし

  This invention provides a preventive or therapeutic agent for autoimmune diseases or inflammatory diseases (especially inflammatory skin diseases) (such as systemic lupus erythematosus, inflammatory bowel disease, psoriasis, rheumatoid arthritis, Sjogren's syndrome, Behcet's disease, multiple sclerosis, atopic dermatitis, etc.) with excellent Tyk2 inhibitory activity. The present invention relates to 3-amino-5-(dicyclopropylmethyl)-7-(4-fluoro-1-methyl-5-(morpholin-4-yl)-1H-pyrazol-3-yl)-1,5-dihydro-4H-pyrazolo[4,3-c]pyridine-4-one, and the like.
• [EN] OXAZOLE AND THIOAZOLE-TYPE CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS D'UBIQUITINE LIGASE CULLIN RING DU TYPE THIOAZOLE ET OXAZOLE ET LEURS UTILISATIONS
  申请人：CEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH

  公开号：WO2021074414A1

  公开（公告）日：2021-04-22

  The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target proteins; i.e. via degradation of a target protein/target proteins by the cullin-RING ubiquitin ligase (CRL). Such target protein/target proteins may be proteins involved in diseases, like cancer, metabolic disorder, infectious disease and/or neurological disorder. The invention further relates to a method for identifying/obtaining and/or testing a compound able to induce ubiquitination of a target protein/target proteins. The invention also relates to the compounds and composition for use as medicaments as well as pharmaceutical compositions comprising these compounds. Particularly, the compounds of the present invention may degrade proteins associated with cancer, metabolic disorder, infectious disease and/or neurological disorder. Furthermore, the present invention relates the compounds for use as a medicament, such as for use in treating cancer, metabolic disorder, infectious disease and/or neurological disorder and to a method for treating a disease, such as cancer, metabolic disorder, infectious disease and/or neurological disorder, comprising administering the compound of the present invention.

  本发明涉及具有刺激/诱导靶蛋白泛素化能力的化合物。本发明的化合物可能通过cullin-RING泛素连接酶（CRL）降解靶蛋白，从而刺激/诱导靶蛋白的泛素化；这些靶蛋白可能是与疾病（如癌症、代谢紊乱、传染病和/或神经疾病）有关的蛋白质。该发明还涉及一种用于识别/获取和/或测试能够诱导靶蛋白泛素化的化合物的方法。该发明还涉及用作药物的化合物和组合物，以及包含这些化合物的药物组合物。特别是，本发明的化合物可能降解与癌症、代谢紊乱、传染病和/或神经疾病相关的蛋白质。此外，本发明涉及用作药物的化合物，例如用于治疗癌症、代谢紊乱、传染病和/或神经疾病，并且涉及一种治疗疾病的方法，如癌症、代谢紊乱、传染病和/或神经疾病，包括给予本发明的化合物。
• EP4 receptor antagonists
  申请人：Clark Edward David

  公开号：US20050124676A1

  公开（公告）日：2005-06-09

  A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein one of R 2 and R 5 is: (i) H or an optionally substituted C 1-4 alkyl group; or (ii)an optionally substituted C 5-7 aryl; and the other of R 2 and R 5 is the other group; m and n can be 0 or 1, and m+n=1 or 2 R N is H or optionally substituted C 1-4 alkyl R 3 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C 1-7 alkyl, C 5-20 aryl, or NR N3 R N4 , where R N3 and R N4 are independently selected from optionally substituted C 1-4 alkyl; or (iv) tetrazol-5-yl.

  化合物的式子为（I）：或其盐，溶剂合物和化学保护形式，其中R2和R5中的一个是：（i）H或可选取代的C1-4烷基；或（ii）可选取代的C5-7芳基；而R2和R5的另一个是另一个基团；m和n可以为0或1，且m+n=1或2。RN为H或可选取代的C1-4烷基。R3是：（i）羧基；（ii）式子（II）的基团；（iii）式子（III）的基团：其中R是可选取代的C1-7烷基，C5-20芳基或NRN3RN4，其中RN3和RN4是独立选择的可选取代的C1-4烷基；或（iv）四唑-5-基。